|

Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Zhejiang University1

Indications

  • RAS1
  • BRAF1
  • Cetuximab1
  • Fruquintinib1
  • Colorectal Neoplasms1

Other1 trial

The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.